Results 121 to 130 of about 13,963,189 (308)

Carry-over effect of immunotherapy in patients with advanced hepatocellular carcinoma

Cancer Immunology, Immunotherapy
Background Combination immunotherapy is the current standard for treating advanced hepatocellular carcinoma (HCC). The response elicited by upfront immune checkpoint inhibitors (ICIs) might influence the efficacy of salvage therapy, a phenomenon known as
Chien-Huai Chuang, Ching-Tso Chen, Chih-Hung Hsu, Yu-Yun Shao   +3 more
doaj   +1 more source

Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia

, 2020
Fostamatinib demonstrated efficacy in phase 3 trials of adults with immune thrombocytopenia (ITP). Post hoc analysis compared patients who received fostamatinib as second‐line therapy (after steroids ± immunoglobulins) versus third‐or‐later‐line therapy (
Bussel, James B., Boccia, Ralph, Ghanima, Waleed Khalid, Hill, Quentin A., Todd, Leslie K., Tong, Sandra, Boxer, Michael A, Cooper, Nichola, Tarantino, Michael D., Sholzberg, Michelle   +9 more
core   +1 more source

Intrapatient tumour heterogeneity and clonal evolution in an autopsy study of metastatic salivary gland cancer

Molecular Oncology, EarlyView.
Tumour heterogeneity and clonal evolution of metastatic salivary gland cancer were evaluated in two patients with adenoid carcinoma and one patient with myoepithelial carcinoma. Radiology‐guided autopsy enabled multi‐region sampling (total samples n = 149), followed by whole‐genome sequencing and phylogenetic reconstruction (17 tumour samples, 4–7 per ...
Gerben Lassche, Niels J. van Ruitenbeek, Charlotte Adang, Luke O'Gorman, Pui Yuen Lee, Willemijn M. Klein, Adriana C. H. van Engen‐van Grunsven, Jack A. Schalken, Sander Bervoets, Gerald W. Verhaegh, Carla M. L. van Herpen   +10 more
wiley   +1 more source

Nilotinib: selective inhibitor as second-line therapy

Clinical Management Issues, 2015
Massimo Breccia
doaj   +1 more source

Extracellular vesicle lipidomics liquid biopsy reveals systemic and tumor microenvironment metabolic reprogramming in ovarian cancer

Molecular Oncology, EarlyView.
Extracellular vesicle (EV) lipidomic profiling of plasma and ascites from patients with high‐grade serous ovarian cancer and of ovarian cancer cell lines reveals enrichment of triglycerides (TGs), diacylglycerols (DGs), phosphatidylcholine (PCs), sphingomyelins (SMs), reflecting tumor metabolic reprogramming.
Shikha Rani, Dominic Guanzon, Andrew Lai, Katherin Scholz‐Romero, Sarah Reed, Edita Ritmejeryte, Rohan Lourie, Naven Chetty, Kaltin Ferguson, Carlos Salomon   +9 more
wiley   +1 more source

A role for eIF5A in translational control of stress‐inducible proteins in multiple myeloma cell lines

Molecular Oncology, EarlyView.
Loss of eIF5A rewires thapsigargin‐mediated endoplasmic reticulum stress responses in multiple myeloma cells by selective translation of mRNA transcripts, consequently dampening thapsigargin‐induced unfolded protein response (UPR) activation and shifting the balance from induction of apoptosis toward cell survival and proliferation.
Demi Both, Ingrid A. M. Derks, Raphaël Vanleyssem, Marine Leclercq, Najla El Hachem, Pierre Close, Eric Eldering, Marco Vincent Haselager   +7 more
wiley   +1 more source

Factors influencing the timing of second-line therapy for the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis

Holistic Integrative Oncology
Purpose The first line palliative treatment medicine contributes modest survival benefit to advanced hepatocellular carcinoma (HCC) patients, but often fails over time.
Xiaoze Zhang, Fangyuan Zhu, Junsong Wen, Ziwei Pan, Yaodong Zhu   +4 more
doaj   +1 more source

Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer

, 2016
To compare treatment outcomes in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel (CA) as second-line or third-line therapy in the everyday clinical setting.
Daugaard, Gedske, Sengeløv, Lisa, Svane, Inge M, Kongsted, Per, Lindberg, Henriette, Bisbjerg, Rasmus   +5 more
core   +1 more source

Regulation of the lncRNA NEAT1 by p53‐ΔNp63 crosstalk modulates the DNA damage response and therapeutic efficacy in HNSCC

Molecular Oncology, EarlyView.
In head and neck squamous cell carcinoma (HNSCC) p53 and p63 exert opposite roles on the transcription regulation of the lncRNA NEAT1. Under basal conditions, p53 levels are low and p63 represses NEAT1 expression. Upon genotoxic stress, p53 is rapidly induced, displacing p63 from the NEAT1 promoter leading to NEAT1 transcriptional activation and ...
Sara De Domenico, Veronica La Banca, Silvia D'Amico, Stefano Scalera, Sara Nicolai, Angelo Peschiaroli   +5 more
wiley   +1 more source

Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data

Cancer Management and Research, 2019
Kei Muro,1 Min-Hua Jen,2 Rebecca Cheng3 1Department of Clinical Oncology, Outpatient Treatment Center, Aichi Cancer Center Hospital, Nagoya, Japan; 2Eli Lilly and Company Ltd, Windlesham, Surrey, UK; 3Eli Lilly and Company, Taipei, Taiwan Purpose: Second-
Muro K, Jen MH, Cheng R
doaj